• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Synergy CHC Corp. Reports First Quarter 2026 Financial Results

    5/14/26 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care
    Get the next $SNYR alert in real time by email

    N. WINDHAM, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three months ended March 31, 2026.

    "Our first quarter results reflect continued execution and the growing momentum of our functional beverage business," said Jack Ross, CEO of Synergy CHC Corp. "During the quarter, we generated over $650,000 in functional beverage revenue, exceeding our total beverage revenue for all of 2025. This performance reflects the success of our expanding retail and distribution partnerships across the U.S., supported by healthy sell-through that is already driving increased reorder activity. Reflecting this momentum, our beverage division is operating at an estimated annual run rate exceeding $4 million. With this foundation in place and continued expansion of our distribution footprint underway, we believe we are well-positioned to capture the significant growth opportunities emerging within the functional beverage sector. With solid early-year momentum and a clear strategic path, we expect 2026 to be a year of sustainable growth and value creation for our shareholders."

    First Quarter 2026 Financial Summary vs. Same Year-Ago Period

    • Revenue of $5.49 million vs. $8.17 million.
    • Gross margin of 72.3% vs. 75.4%.
    • Income (loss) from operations of ($0.57) million vs. $1.95 million.
    • Net income (loss) of ($2.57) million vs. $0.88 million.
    • Earnings (loss) per share of ($0.23) vs. $0.10.
    • EBITDA (loss), a non-GAAP financial measure, was ($0.54) million vs. $1.98 million.
    • Adjusted EBITDA (loss), a non-GAAP financial measure, was $(0.35) million vs. $1.98 million.



    First Quarter 2026 Financial Results

    Revenue in the first quarter of 2026 was $5.49 million compared to $8.17 million in the first quarter of 2025, due to license revenue of $1.5 million in 2025 that did not repeat in 2026 and out-of-stock dynamics for several key online items in our Flat Tummy brand, which impacted online sales. This was partially offset by strong performance in beverages, which delivered significantly higher revenue compared to the prior year period.

    Gross margin in the first quarter of 2026 was 72.3% compared to 75.4% in the first quarter of 2025. Excluding license revenue from the first quarter of 2025, normalized gross margin for that period was 70.0%, a 2.3% improvement year-over-year.

    Operating expenses in the first quarter of 2026 were $4.54 million compared to $4.22 million in the first quarter of 2025, reflecting higher overhead associated with the expansion of the beverage business.

    Income (loss) from operations for the first quarter of 2026 was ($0.57) million compared to $1.95 million in the first quarter of 2025, which is largely due to the license revenue of $1.5 million in 2025 that did not repeat in 2026 and increased overhead costs.

    Net income (loss) in the first quarter of 2026 was ($2.57) million compared to net income of $0.88 million in the first quarter of 2025.

    Earnings (loss) per share in the first quarter of 2026 was ($0.23) compared to $0.10 in the first quarter of 2025.

    EBITDA (loss) (a non-GAAP financial measure) in the first quarter of 2026 was ($0.54) million compared to $1.98 million in the first quarter of 2025.

    Adjusted EBITDA (loss) (a non-GAAP financial measure) in the first quarter of 2026 was $(0.35) million compared to $1.98 million in the first quarter of 2025.

    Balance Sheet and Cash Flow

    As of March 31, 2026, Synergy had approximately $0.30 million in cash and cash equivalents, compared to $2.6 million in cash and cash equivalents as of December 31, 2025. Subsequent to quarter-end, Synergy raised approximately $2.7 million in gross proceeds through its at-the-market (ATM) equity offering program.

    As of March 31, 2026, Synergy had a working capital deficit of $0.50 million, compared to a $1.78 million working capital surplus as of December 31, 2025.

    As of March 31, 2026, Synergy had $3.4 million in inventory, compared to $3.7 million in inventory as of December 31, 2025.

    Cash used in operating activities for the three months ended March 31, 2026 was $2.0 million compared to cash used in operating activities of $0.82 million for the three months ended March 31, 2025.

    Non-GAAP Financial Measure Reconciliation: EBITDA and Adjusted EBITDA

    To assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors' overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.

    Management believes EBITDA and Adjusted EBITDA provide useful information to investors by excluding certain items that may not be indicative of the Company's core operating results and that can vary significantly between periods. EBITDA is defined as net income plus interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is calculated as EBITDA plus or minus foreign exchange gains or losses, one-time expenses and non-cash expenses. Since Adjusted EBITDA is a non-GAAP financial performance measure, the Company's calculation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies; and should not be considered in isolation, as a substitute for, or superior to measures of financial performance prepared in accordance with GAAP.

    The following table reconciles net income to EBITDA and Adjusted EBITDA (in millions of US dollars):

      
     3 Months ended March 31
      2026  2025 
       
    Net (loss) income for the period$ (2.57) $ 0.88 
    Adjusted for:  
    Interest expense, net 2.01  1.08 
    Amortization of intangible assets 0.03  0.03 
    Tax benefit (0.01)  (0.01) 
    EBITDA$ (0.54) $ 1.98 
    Foreign currency adjustment (0.00  0.00 
    Stock based compensation 0.16  - 
    Board expenses 0.03  - 
    Adjusted EBITDA$(0.35) $1.98 



    About Synergy CHC Corp.

    Synergy CHC Corp. develops and markets consumer health and wellness products, led by its flagship brands FOCUSfactor® and Flat Tummy®. FOCUSfactor®, a clinically studied brain health supplement and functional beverage line with a 25-year legacy, enjoys established distribution in the U.S., Canada and Mexico. through major retailers including Costco, Walmart, Amazon, BJ's, and Walgreens, among others. Flat Tummy® complements Synergy's portfolio as a lifestyle brand focused on women's wellness and weight management.

    Forward Looking Statements

    Certain statements contained in this press release constitute "forward-looking statements," including statements regarding brand expansion and growth initiatives. These forward-looking statements represent Synergy's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy's registration statement on Form S-1, as amended, many of which are outside of Synergy's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

    Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy's filings with the SEC. The risk factors and other factors noted in Synergy's filings could cause its actual results to differ materially from those contained in any forward-looking statement.

    Investor Relations



    Gateway Group

    Cody Slach, Greg Robles

    949.574.3860

    SNYR@gateway-grp.com



    Synergy CHC Corp.

    Condensed Consolidated Balance Sheets

           
      March 31, 2026  December 31,

    2025
     
      (unaudited)    
    Assets      
    Current Assets      
    Cash and cash equivalents $292,115  $      2,622,313 
    Restricted cash  100,000   100,000 
    Accounts receivable, net  1,268,022   3,203,505 
    Prepaid expenses (including related party amount of $652,270 and $110,803, respectively)  1,303,173   351,049 
    Inventory, net  3,381,614   3,737,509 
    Total Current Assets  6,344,924   10,014,376 
             
    Intangible assets, net  116,667   150,000 
             
    Total Assets $6,461,591  $10,164,376 
             
    Liabilities and Stockholders' Deficit        
    Current Liabilities:        
    Accounts payable and accrued liabilities (including payable to shareholder of $193,641 and $197,512, respectively) $4,031,994  $6,388,219 
    Income taxes payable  85,811   88,108 
    Contract liabilities  -   1,526 
    Short term loans payable, net of debt discount, related party  -   100,000 
    Current portion of notes payable, net of debt discount  2,730,981   1,658,215 
    Total Current Liabilities  6,848,786   8,236,068 
             
    Long-term Liabilities:        
    Notes payable, net of debt discount  25,018,055   25,056,446 
    Total long-term liabilities  25,018,055   25,056,446 
    Total Liabilities  31,866,841   33,292,514 
             
    Commitments and contingencies        
             
    Stockholders' Deficit:        
    Common stock, $0.00001 par value; 300,000,000 shares authorized; 11,483,926 shares issued; 11,303,853 outstanding  114   114 
    Additional paid in capital  33,710,857   33,594,550 
    Common stock to be issued  153,400   - 
    Accumulated other comprehensive loss  (132,201)  (154,281)
    Accumulated deficit  (59,009,920)  (56,441,021)
    Less: Treasury stock (180,073 shares) at cost  (127,500)  (127,500)
    Total stockholders' deficit  (25,405,250)  (23,128,138)
    Total Liabilities and Stockholders' Deficit $6,461,591  $10,164,376 





    Synergy CHC Corp.

    Unaudited Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income

           
      For the

    three months

    ended
      For the

    three months

    ended
     
      March 31,

    2026
      March 31,

    2025
     
    Revenue      
    Product Sales $5,492,705  $     6,670,534 
    License Revenue  -   1,500,000 
    Total Revenue  5,492,705   8,170,534 
             
    Cost of Sales  1,521,910   2,006,513 
             
    Gross Profit  3,970,795   6,164,021 
             
    Operating expenses        
    Selling and marketing  2,455,732   2,876,271 
    General and administrative  2,048,850   1,306,714 
    Depreciation and amortization  33,333   33,333 
    Total operating expenses  4,537,915   4,216,318 
             
    (Loss) Income from operations  (567,120)  1,947,703 
             
    Other (income) expenses        
    Interest income  (340)  (13,882)
    Interest expense  2,012,121   1,095,369 
    Remeasurement loss on translation of foreign subsidiary  3,718   1,412 
             
    Total other expenses  2,015,499   1,082,899 
             
    Net (loss) income before income taxes  (2,582,619)  864,804 
    Income tax benefit  13,720   11,460 
             
    Net (loss) income after tax $(2,568,899) $876,264 
             
    Net (loss) income per share – basic $(0.23) $0.10 
    Net (loss) income per share – diluted $(0.23) $0.10 
             
    Weighted average common shares outstanding        
    Basic  11,303,853   8,560,636 
    Diluted  11,303,853   8,577,620 
    Comprehensive (loss) income:        
    Net (loss) income $(2,568,899) $876,264 
    Foreign currency translation adjustment  22,080   (1,935)
    Comprehensive (loss) income $(2,546,819) $874,329 







    Synergy CHC Corp.

    Unaudited Condensed Consolidated Statements of Cash Flows 

           
      For the

    three months

    ended
      For the

    three months

    ended
     
      March 31,

    2026
      March 31,

    2025
     
    Cash Flows from Operating Activities      
    Net (loss) income $(2,568,899) $876,264 
    Adjustments to reconcile net (loss) income to net cash used in operating activities:        
    Amortization of debt discount and debt issuance cost  951,942   406,841 
    Depreciation and amortization  33,333   33,333 
    Stock based compensation  116,307   - 
    Foreign currency transaction loss (gain)  2,684   (3,137)
    Remeasurement loss (gain) on translation of foreign subsidiary  3,718   (1,412)
    Changes in operating assets and liabilities:        
    Accounts receivable  1,935,483   940,519 
    Other receivables  -   144,637 
    Loan receivable, related party  -   (833)
    Inventory  355,895   (629,935)
    Prepaid expenses  (410,657)  (114,787)
    Prepaid expense, related party  (541,467)  (195,913)
    Income taxes payable  (2,297)  (165,413)
    Contract liabilities  (1,526)  (24,216)
    Accounts payable and accrued liabilities  (1,915,323)  (2,218,041)
    Accounts payable, related party  (3,871)  129,312 
    Net cash used in operating activities  (2,044,678)  (822,781)
             
    Cash Flows from Investing Activities  -   - 
             
    Cash Flows from Financing Activities        
    Advances from related party  -   135,000 
    Repayment of notes payable, related party  (100,000)  - 
    Proceeds from notes payable  2,660,000   1,496,250 
    Payment of loan financing fees  (55,000)  - 
    Repayment of notes payable  (2,812,600)  (1,316,572)
    Net cash (used in) provided by financing activities  (307,600)  314,678 
             
    Effect of exchange rate on cash, cash equivalents and restricted cash  22,080   (1,935)
    Net decrease in cash, cash equivalents and restricted cash  (2,330,198)  (510,038)
             
    Cash and restricted cash, beginning of year  2,722,313   787,920 
    Cash and restricted cash, end of period $392,115  $277,882 
             
    Supplemental Disclosure of Cash Flow Information:        
    Cash paid during the period for:        
    Interest $392,846  $573,529 
    Income taxes $-  $- 
             
    Supplemental Disclosure of Noncash Investing and Financing Activities:        
    Issuance of common stock for accounts receivable advance financing $-  $117,648 
    Loan financing fees, accrued $110,000  $- 
    Capitalized interest on senior debt $400,033  $- 
    Common stock to be issued for accounts receivable advance financing $153,400  $- 





    Primary Logo

    Get the next $SNYR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNYR

    DatePrice TargetRatingAnalyst
    2/2/2026$5.00Buy
    Ascendiant Capital Markets
    1/21/2025$10.00Buy
    ROTH MKM
    More analyst ratings

    $SNYR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital Markets initiated coverage on Synergy CHC Corp. with a new price target

    Ascendiant Capital Markets initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $5.00

    2/2/26 6:52:55 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    ROTH MKM initiated coverage on Synergy CHC Corp. with a new price target

    ROTH MKM initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $10.00

    1/21/25 9:10:17 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kaushal Nitin was granted 306,433 shares (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    4/24/26 9:12:09 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Director Thompson Teresa Brigid was granted 25,824 shares (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    4/23/26 9:24:12 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form 3 filed by new insider Thompson Teresa Brigid

    3 - Synergy CHC Corp. (0001562733) (Issuer)

    10/2/25 9:47:13 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Synergy CHC Corp. Reports First Quarter 2026 Financial Results

    N. WINDHAM, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three months ended March 31, 2026. "Our first quarter results reflect continued execution and the growing momentum of our functional beverage business," said Jack Ross, CEO of Synergy CHC Corp. "During the quarter, we generated over $650,000 in functional beverage revenue, exceeding our total beverage revenue for all of 2025. This performance reflects the success of our expanding retail and distribution partnerships across the U.S., supported by healthy sell-through that is already driving incr

    5/14/26 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

    NORTH WINDHAM, Maine, April 01, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three and twelve months ended December 31, 2025. "Our full year results reflect a year of meaningful strategic progress and continued advancement of our priority growth initiatives," said Jack Ross, CEO of Synergy CHC Corp. "During 2026 on the beverage side, we have shipped our Focus and Energy RTDs and shots into several new key distribution partners, including EG America, Wakefern Food, and Pine State Beverage, to name a few. With millions of cans of RTDs and shots in stock and ready to

    4/1/26 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference Call

    WESTBROOK, Maine, March 30, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced an updated date for the release of its fourth quarter and full year financial results ended December 31, 2025. The Company will now report its financial results on Wednesday, April 1, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be avail

    3/30/26 5:14:41 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman Ross Jack bought $79,578 worth of shares (27,900 units at $2.85), increasing direct ownership by 7% to 410,507 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    7/31/25 8:31:46 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    CEO and Chairman Ross Jack bought $29,837 worth of shares (16,100 units at $1.85), increasing direct ownership by 4% to 382,607 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    6/11/25 7:17:28 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    CEO and Chairman Ross Jack bought $10,870 worth of shares (5,300 units at $2.05), increasing direct ownership by 1% to 366,507 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    5/21/25 5:05:31 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    SEC Filings

    View All

    SEC Form EFFECT filed by Synergy CHC Corp.

    EFFECT - Synergy CHC Corp. (0001562733) (Filer)

    5/26/26 12:15:25 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Synergy CHC Corp. (0001562733) (Filer)

    5/18/26 9:01:37 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form S-1 filed by Synergy CHC Corp.

    S-1 - Synergy CHC Corp. (0001562733) (Filer)

    5/15/26 5:07:04 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Leadership Updates

    Live Leadership Updates

    View All

    Synergy CHC Corp. (NASDAQ: SNYR) Appoints Pedro Colmenares as Director of Sales & Marketing for Mexico & Latin America

    WESTBROOK, Maine, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced that Pedro Colmenares has been appointed Director of Sales & Marketing for Mexico & Latin America. In this role, Mr. Colmenares will lead commercial strategy, market expansion, and go-to-market execution across the region. Mr. Colmenares joins the Company at a pivotal time as it advances its international growth strategy. As announced in May 2025, Synergy established a wholly owned subsidiary in Mexico and has begun its initial market entry through shipments of its supplement products to Costco Mexico this week. A

    12/16/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Lead Strategic Partnerships; Appoints Veteran Costco Buyer to Board of Directors

    Board member Scott Woodburn transitions to Head of Strategic Partnerships to accelerate FOCUSfactor Energy Drink expansion Former Costco Buyer Teresa Thompson brings nearly 40 years of retail expertise in vitamins and supplements WESTBROOK, Maine, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced two key leadership changes: Scott Woodburn has been appointed to Head of Strategic Partnerships to drive the Company's expansion in functional beverages, and Teresa Thompson has been appointed to Synergy's Board of Directors (the "Board"), effective immediately. In connection with Woodb

    9/22/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global Expansion

    WESTBROOK, Maine, June 10, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a fast-growing consumer health and wellness company, announced today that Damian Marano has been named Vice President of Beverage, effective immediately. This appointment marks a major milestone in the Company's aggressive push into the booming functional beverage market. "We're excited to welcome Damian to Synergy's executive leadership team," said Jack Ross, CEO of Synergy CHC Corp. "Damian's deep expertise in beverage, CPG, and technology-enabled growth adds another high-caliber industry veteran to further guide our beverage business through its next phase. His proven track

    6/10/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Financials

    Live finance-specific insights

    View All

    Synergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

    NORTH WINDHAM, Maine, April 01, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three and twelve months ended December 31, 2025. "Our full year results reflect a year of meaningful strategic progress and continued advancement of our priority growth initiatives," said Jack Ross, CEO of Synergy CHC Corp. "During 2026 on the beverage side, we have shipped our Focus and Energy RTDs and shots into several new key distribution partners, including EG America, Wakefern Food, and Pine State Beverage, to name a few. With millions of cans of RTDs and shots in stock and ready to

    4/1/26 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference Call

    WESTBROOK, Maine, March 30, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced an updated date for the release of its fourth quarter and full year financial results ended December 31, 2025. The Company will now report its financial results on Wednesday, April 1, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be avail

    3/30/26 5:14:41 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Fourth Quarter and Full Year 2025 Earnings and Conference Call Information

    WESTBROOK, Maine, March 17, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's websi

    3/17/26 4:05:00 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Synergy CHC Corp.

    SC 13D - Synergy CHC Corp. (0001562733) (Subject)

    10/31/24 9:55:58 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Synergy CHC Corp.

    SC 13G - Synergy CHC Corp. (0001562733) (Subject)

    10/25/24 7:46:44 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care